Literature DB >> 35037226

Clinical usefulness of the CSF β-amyloid Aβ1-42/Aβ1-40 ratio for Alzheimer's disease diagnosis: a retrospective study in a Belgian academic hospital.

Matthieu Deltombe1, Catherine Fillee1, Vincent van Pesch2.   

Abstract

Entities:  

Keywords:  Alzheimer; Aβ1-40; Aβ1-42; Cerebrospinal fluid; Ratio

Mesh：

Substances：

Year:  2022        PMID： 35037226     DOI： 10.1007/s13760-021-01846-4

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN： 0300-9009            Impact factor:   2.396


× No keyword cloud information.
  6 in total

1.  Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ42 and T-Tau assays for Alzheimer's disease diagnosis.

Authors:  Jean-Louis Bayart; Bernard Hanseeuw; Adrian Ivanoiu; Vincent van Pesch
Journal:  J Neurol       Date:  2019-06-10       Impact factor: 4.849

Review 2.  Clinical validity of cerebrospinal fluid Aβ42, tau, and phospho-tau as biomarkers for Alzheimer's disease in the context of a structured 5-phase development framework.

Authors:  Niklas Mattsson; Anders Lönneborg; Marina Boccardi; Kaj Blennow; Oskar Hansson
Journal:  Neurobiol Aging       Date:  2017-04       Impact factor: 4.673

Review 3.  Biomarkers for Alzheimer Disease: Classical and Novel Candidates' Review.

Authors:  Nadia El Kadmiri; Nadia Said; Ilham Slassi; Bouchra El Moutawakil; Sellama Nadifi
Journal:  Neuroscience       Date:  2017-07-17       Impact factor: 3.590

Review 4.  NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Billy Dunn; Samantha Budd Haeberlein; David M Holtzman; William Jagust; Frank Jessen; Jason Karlawish; Enchi Liu; Jose Luis Molinuevo; Thomas Montine; Creighton Phelps; Katherine P Rankin; Christopher C Rowe; Philip Scheltens; Eric Siemers; Heather M Snyder; Reisa Sperling
Journal:  Alzheimers Dement       Date:  2018-04       Impact factor: 21.566

Review 5.  Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer's Disease.

Authors:  Oskar Hansson; Sylvain Lehmann; Markus Otto; Henrik Zetterberg; Piotr Lewczuk
Journal:  Alzheimers Res Ther       Date:  2019-04-22       Impact factor: 6.982

6.  CSF Aβ42/Aβ40 and Aβ42/Aβ38 ratios: better diagnostic markers of Alzheimer disease.

Authors:  Shorena Janelidze; Henrik Zetterberg; Niklas Mattsson; Sebastian Palmqvist; Hugo Vanderstichele; Olof Lindberg; Danielle van Westen; Erik Stomrud; Lennart Minthon; Kaj Blennow; Oskar Hansson
Journal:  Ann Clin Transl Neurol       Date:  2016-01-01       Impact factor: 4.511
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.